Dear Editor,

SARS-CoV2 is a novel coronavirus responsible for a potentially life-threatening infectious disease named COVID-19. Currently, there is no effective treatment for SARS-CoV2, and COVID-19 is managed with symptomatic therapies and supportive care.

In inflammatory bowel disease (IBD), immunosuppressive drugs may increase the risk of infection and/or of severe clinical forms of COVID-19 \[[@bib0001],[@bib0002]\]. Therefore, IBD management in patients with concurrent COVID-19 is particularly challenging. International expert recommendations suggest to delay immunosuppressive therapy for at least 2 weeks in patients in remission with active infection [@bib0003]. Moreover, the optimal therapeutic strategy for patients with an acute severe ulcerative colitis (UC) and concurrent SARS-CoV2 infection is not established. Intravenous corticosteroids are usually the mainstay treatment for these patients. Recent data associated corticosteroid treatment with a higher patient\'s mortality compared to anti-TNF antibodies even though a subgroup analysis according to the disease activity (i.e. remission, mild or severe flares) was not performed [@bib0004]. Additionally, a letter from Italy reported a severe deadly COVID-19 pneumonia in a 80-year-old woman with a severe UC flare treated by corticosteroids [@bib0005].

Recently, we admitted a 20 year-old Somalian woman with UC diagnosed a year earlier, presenting a moderately severe UC flare with intense fatigue, abdominal pain and bloody diarrhoea. The patient was not on maintenance therapy because of a concurrent diagnosis of multidrug resistant miliary tuberculosis. At admission, the Lichtiger score was at 10. Laboratory analysis showed mild anemia and increased C-reactive protein ([Table 1](#tbl0001){ref-type="table"} ). A nasal swab for SARS-CoV2 was performed and resulted positive. Stool culture, *C. Difficile* toxin test and stool SARS-CoV2 RT-PCR were negative. A CT scan showed a pancolitis but no pulmonary lesions suggestive of COVID-19 pneumonia ([Fig. 1](#fig0001){ref-type="fig"}). Table 1Laboratory parameters.Table 1Day 0Day 7Day 12Day 15SARS-CoV2 RT-PCRPositivePositiveNANegativeTreatmentNo5-ASACTCCTCHemoglobin (g/dl)1110.510.110C-reactive protein (mg/l)1812296.515.3Albumin (g/l)39343427Stools/day9786Bloody stools (%)\<50%\<50%\<50%0Lichtiger score1013135[^2]Fig. 1CT scan showing colitis extended to transverse colon (A, arrows) and hepatic flexure (B, \*).Fig 1

Since systemic corticosteroids use in influenza patients has been associated with a significantly higher risk of lower respiratory tract infection and complications, we first decided to treat the patient with a combination of oral and rectal 5-aminosalicylic acid (4g/day p.o. and 1g/day locally). After 1 week, the patient did not improve and the Lichtiger score increased to 13. A flexible sigmoidoscopy showed a complete vascular pattern obliteration, multiple superficial ulcerations and pseudopolyps (UCEIS: 7/8). A nasal swab for SARS-CoV2 was repeated and resulted positive. As the patient was at low risk of developing a severe form of COVID-19 and her UC severity was worsening, we decided to start methylprednisolone 40 mg/day IV. The patient quickly improved at day 3 (Lichtiger score at 5) and did not develop any COVID-19 symptoms or complications. Laboratory parameters improved significantly ([Table 1](#tbl0001){ref-type="table"}).

Acute severe ulcerative colitis is a life-threatening complication of UC and intravenous corticosteroids are the first-line therapy. Corticosteroids in IBD patients with SARS-CoV2 infection have been associated initially with worse outcomes [@bib0004]. However, in low-risk patients with asymptomatic SARS-CoV2 and acute severe UC, whether the risk associated with corticosteroids overweight the benefit is not clear. Recent data suggest a benefit of dexamethasone on the inflammatory state induced by COVID-19 in patients with respiratory failure [@bib0006] even though these results should still be taken with caution due to several study limitations such as the fact that at least 28% of participating patients were still hospitalized at the endpoint of the trial (day 28) [@bib0007].

Taking into account risk factors of severe COVID-19 (in particular age) is probably essential before using corticosteroids. In the SECURE-IBD database, 50% of IBD patients who died from COVID-19 and 73% who died and/or needed hospitalisation in an intensive care unit and/or requested invasive ventilation were 60 years or older (respectively 28% and 31% for patient ≥ 80 years old; *n*=1696) [@bib0008]. In our experience, the use of corticosteroids in a young adult patient in the second week of SARS-CoV2 infection was safe and effective for treating an acute severe UC flare.
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